Sun, Apr 20, 2014, 10:46 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • dinepat203 dinepat203 Nov 26, 2012 9:57 AM Flag

    SRPT $30 ON RNA splicing modulator, The most advanced antisense drug, mipomersen, marketing approval in Europe

    Splicing & Its Role in Disease

    Splicing is a normal mechanism that the cell uses in order to produce many
    different, but closely related proteins from a single gene by varying the processing
    of the RNA. It is estimated that of the approximately 25,000 genes in the human
    genome, approximately 90 percent have alternative splice forms. In some cases,
    alternative splicing results in diseases, such as SMA, where alternative splicing
    inhibits the production of a functional protein necessary for normal motor function.


    Antisense Therapeutics
    Antisense drugs are small (12-21 nucleotides) DNA- or RNA-like compounds that
    are chemically modified to engineer good drug properties. Isis’ antisense drugs
    have been evaluated extensively in both animals and man with more than 5,000
    subjects dosed with Isis’ antisense drugs. Isis has conducted approximately 80
    clinical trials in more than a dozen different patient populations from
    cardiovascular to cancer. The most advanced antisense drug, mipomersen,
    completed a broad Phase 3 program in patients with high cholesterol and is
    currently being evaluated for marketing approval in Europe.

    ISIS-SMNRx
    Isis’ drug, ISIS-SMNRx
    is designed to modulate the splicing of the SMN2 gene to
    significantly increase the production of functional SMN protein. In previously
    published results, researchers showed that ISIS-SMNRx produced sustained
    activity in mouse models of SMA and that target tissue concentrations were
    achieved in non-human primates following a single intrathecal injection.
    Isis Pharmaceuticals is a leader in antisense technology to discover and develop novel drugs. Isis’ broad drug pipeline consists of 24 drugs in development designed to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare/neurodegenerative diseases and cancer.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ISIS
34.01-0.56(-1.62%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.